Peculiarities of placental factors content in women in pregnancies resulting from in vitro fertilization

Akimova A.A.; Malyshkina A.I.; Nazarov S.B.; Popova I.G.; Klycheva M.M.; Kuz’menko G.N.

doi:https://doi.org/10.17116/rosakush2024240515

Akimova A.A.

V.N. Gorodkov Ivanovo Scientific-Research Institute of Maternity and Childhood

ORCID: 0009-0004-2463-2093

Malyshkina A.I.

Ivanovo State Research Institute of Maternity and Childhood n.a. V.N. Gorodkov

SPIN RSCI: 7937-9125
Scopus AuthorID: 7801326390
ResearcherID: B-5680-2017
ORCID: 0000-0002-1145-0563

Nazarov S.B.

V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood

ORCID: 0000-0003-1545-7655

Popova I.G.

V.N. Gorodkov Ivanovo Scientific-Research Institute of Maternity and Childhood

ORCID: 0000-0003-1836-3523

Klycheva M.M.

V.N. Gorodkov Scientific Research Institute of Maternity and Childhood

ORCID: 0000-0002-1725-8505

Kuz’menko G.N.

V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood

ORCID: 0000-0001-5772-9271

Peculiarities of placental factors content in women in pregnancies resulting from in vitro fertilization

Authors:

Akimova A.A., Malyshkina A.I., Nazarov S.B., Popova I.G., Klycheva M.M., Kuz’menko G.N.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2024;24(5): 5‑11

DOI: 10.17116/rosakush2024240515

Read: 595 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Akimova AA, Malyshkina AI, Nazarov SB, Popova IG, Klycheva MM, Kuz’menko GN. Peculiarities of placental factors content in women in pregnancies resulting from in vitro fertilization. Russian Bulletin of Obstetrician-Gynecologist. 2024;24(5):5‑11. (In Russ.)
https://doi.org/10.17116/rosakush2024240515

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Abstract:

OBJECTIVE

To study the peculiarities of placental factors production in pregnancies resulting from in vitro fertilization (IVF) at 11—14 weeks gestation.

MATERIAL AND METHODS

152 patients with 11-14 weeks’ gestation were examined. The main group consisted of 82 patients with pregnancy after IVF — fresh embryo transfer with native stimulation. The control group included 70 patients with spontaneous pregnancy. Clinical and anamnestic evaluation of the patients and ultrasound examination were performed. The following placental factors were determined in serum by enzyme immunoassay: levels of vascular endothelial growth factor type A (VEGF-A), soluble vascular endothelial growth factor receptor type 1 (sVEGF-R1), placental growth factor (PIGF), trophoblastic β-1-glycoprotein (TBG). Free beta-subunit of human chorionic gonadotropin (β-hCG) and pregnancy-associated protein A (PARP-A) were assessed.

RESULTS

Patients of both groups were comparable in age, social status, frequency of infectious diseases, and extragenital pathology. Inflammatory gynecologic diseases, endometriosis were statistically significantly more frequent among the patients of the main group, infertility was established in 100% of observations. As a result of the study of biochemical markers of fetoplacental system function in the patients of the main group at 11-14 weeks of gestation, a statistically significant increase in VEGF-A (p=0.001) and a decrease in sVEGF-R1 levels (p=0.001) were found. The “Method for predicting the threat of pregnancy termination in the II trimester in the form of threatening late miscarriage and threatening preterm labor in women with pregnancy resulting from IVF” was developed (invention patent No. 2784346 dated 23.11.2022).

CONCLUSION

Application of the developed method of predicting the development of threatening pregnancy termination in the II trimester — threatening late miscarriage and/or threatening preterm labor in women with pregnancy resulting from IVF, allows to provide a personalized approach to the management of these pregnant women, as well as to timely conduct preventive and therapeutic measures to prolong pregnancy and improve perinatal outcome.

Keywords:

pregnancy at 11-14 weeks due to in vitro fertilization

physiological pregnancy at 11-14 weeks

biochemical markers of fetoplacental system function

statistically significant increase in vascular endothelial growth factor type A

decreased levels of soluble vascular endothelial growth factor receptor type 1

method of predicting the threat of pregnancy termination (threatened late miscarriage and/or threatened preterm labor in the II trimester)

Authors:

Akimova A.A.

V.N. Gorodkov Ivanovo Scientific-Research Institute of Maternity and Childhood

ORCID: 0009-0004-2463-2093

Malyshkina A.I.

Ivanovo State Research Institute of Maternity and Childhood n.a. V.N. Gorodkov

SPIN RSCI: 7937-9125
Scopus AuthorID: 7801326390
ResearcherID: B-5680-2017
ORCID: 0000-0002-1145-0563

Nazarov S.B.

V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood

ORCID: 0000-0003-1545-7655

Popova I.G.

V.N. Gorodkov Ivanovo Scientific-Research Institute of Maternity and Childhood

ORCID: 0000-0003-1836-3523

Klycheva M.M.

V.N. Gorodkov Scientific Research Institute of Maternity and Childhood

ORCID: 0000-0002-1725-8505

Kuz’menko G.N.

V.N. Gorodkov Ivanovo Research Institute of Maternity and Childhood

ORCID: 0000-0001-5772-9271

Received:

01.02.2024

Accepted:

22.02.2024

Close metadata

References:

Serebrennikova K.G., Kuznetsova E.P., Banke E.S., Ivanova T.V., Miloslavskii Yu.V. Pregravidar preparation in patients with a thin endometrium in assisted reproductive technology programs. Akusherstvo i ginekologiya. 2017;3:139-146. (In Russ.).
Trifonova N.S., Zhukova E.V., Grineva A.M., Aleksandrov L.S., Ishchenko A.I., Nikonov A.P., Soboleva V.V. Clinical features of the course of pregnancy, labor, delivery, and perinatal outcomes in women after in vitro fertilization using donor oocytes. Russian Bulletin of Obstetrician-Gynecologist. 2017;17:1:46-52. (In Russ.). https://doi.org/10.17116/rosakush201717146-52
Pinborg A, Wennerholm UB, Romundstad LB, Loft A, Aittomaki K, Söderström-Anttila V, Nygren KG, Hazekamp J, Bergh C. Why do singletons conceived after assisted reproduction technology have adverse perinatal outcome? Systematic review and meta-analysis. Hum Reprod Update. 2013;19:2:87-104. https://doi.org/10.1093/humupd/dms044
Okun N, Sierra S. Pregnancy outcomes after assisted human reproduction. J Obstet Gynaecol Can. 2014;36:1:64-83. https://doi.org/10.1016/S1701-2163(15)30685-X
Sullivan-Pyke CS, Senapati S, Mainigi MA, Barnhart KT. In vitro fertilization and adverse obstetric and perinatal outcomes. Semin Perinatol. 2017;41:6:345-353. https://doi.org/10.1053/j.semperi.2017.07.001
Kamath MS, Kirubakaran R, Mascarenhas M, Sunkara SK. Perinatal outcomes after stimulated versus natural cycle IVF: a systematic review and meta-analysis. Reprod BioMed Online. 2018;36:1:94-101. https://doi.org/10.1016/j.rbmo.2017.09.009
Podzolkova N.M., Skvortsova M.Yu, Prilutskaya S.G. Pregnancy after IVF: risk factors of complications. Russian Journal of Human Reproduction. 2020;26:2:120-131. (In Russ.). https://doi.org/10.17116/repro202026021120
Gazieva I.A., Remizova I.I., Chistyakova G.N., Deryabina E.G. Prognostic value of clinical, anamnestic, microbiological, and biochemical factors in the genesis of early reproductive losses unassociated with fetal chromosomal abnormalities. Russian Bulletin of Obstetrician-Gynecologist. 2014;14:5:54-59. (In Russ.).
Ziganshina M.M., Krechetova L.V., Van’ko L.V., Khodzhaeva Z.S., Musienko E.V., Sukhikh G.T. Pro and antiangiogenic factors in the pathogenesis of early pregnancy losses. Part I. The specific features of pro and antiangiogenic serum factors in early pregnancy. Akusherstvo i ginekologija. 2012;3:14-19. (In Russ.).
Forbes K, Westwood M. Maternal growth factor regulation of human placental development and fetal growth. J Endocrinol. 2010;207:1:1-16. https://doi.org/10.1677/JOE-10-0174
Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J Immunol. 2009;182:7:4085-4092. https://doi.org/10.4049/jimmunol.0803769
Plaisier M, Dennert I, Rost E, Koolwijk P, van Hinsbergh VW, Helmerhorst FM. Decidual vascularization and the expression of angiogenic growth factors and proteases in first trimester spontaneous abortions. Hum Reprod. 2009;24:1:185-197. https://doi.org/10.1093/humrep/den296
Wathén KA, Tuutti E, Stenman UH, Alfthan H, Halmesmäki E, Finne P, Ylikorkala O, Vuorela P. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006;91:1:180-184. https://doi.org/10.1210/jc.2005-1076
Mac Gabhann F, Popel AS. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol. 2004;286(1):H153—H164. https://doi.org/10.1152/ajpheart.00254.2003
Posiseeva L.V., Nazarov S.B., Tatarinov Yu.S. Trophoblast-specific beta-glycoprotein in obstetrics and gynecology. Ivanovo: Ivanovo. 2004;238. (In Russ.).
Bogdanovich R.N., Chikalovets I.V., Berestovaya T.A. Trophoblastic beta1-glycoprotein in clinical practice (literature review). Klinicheskaya laboratornaya diagnostika. 2004;2:3-8. (In Russ.).
Tsibizova V.I., Govorov I.E., Pervunina T.M., Komlichenko E.V., Kudryashova E.K., Blinov D.V., Makatsariya A.D., Di Renco D.K. First trimester prenatal screening in multiple pregnancies. Part I: comparative analysis of serum proteins PAPP-A and β-HCG in pregnancies conceived spontaneously or by in vitro fertilization. Akusherstvo, Ginekologiya i reproduktsiya. 2020;14:1:25-33. (In Russ.). https://doi.org/10.17749/2313-7347.2020.14.1.25-33
RL: https://science-education.ru/ru/article/view?id=20811(InRuss.).
https://www1.fips.ru/ofpstorage/BULLETIN/IZPM/2022/11/27/INDEX_RU.HTM https://www1.fips.ru/ofpstorage/BULLETIN/IZPM/2022/11/27/INDEX_RU.HTM
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A Crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2:12:1097-1105. https://doi.org/10.1177/1947601911423031
Demchenko N.S., Bashmakova N.V., Tret’yakova T.B. Pathogenesis of the pregnancy loss: role of the vascular endothelial growth factor (VEGF-A). Ural’skii meditsinskii zhurnal. 2012;11:6. (In Russ.).
Dobrokhotova Yu.E., Borovkova E.I. Ovarian hyperstimulation: modern tactics of managing patients. Ginekologiya. 2017;19:2:19-22. (In Russ.).
Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem. 2013;153:1:13-19.
Kazantseva E.V. The contents of the placental proteins in pregnant women with growth retardation depending on the exposure to anthropogenic chemicals. Zabaikal’skii meditsinskii vestnik. 2016;4:89-93. (In Russ.).
Zamorina S.A., Raev N.B. Immunomodulating effects of human pregnancy-specific β1-glycoprotein. Fiziologiya cheloveka. 2015;41:1:117-123. (In Russ.).